Literature DB >> 8339128

Progression of sialadenitis in Sjögren's syndrome.

R Jonsson1, U Kroneld, K Bäckman, B Magnusson, A Tarkowski.   

Abstract

An analysis of progression of sialadenitis in patients with primary and secondary SS has been performed. For this purpose patients were prospectively followed and evaluated with respect to stimulated whole salivary secretion and morphology of labial salivary gland biopsies. Twenty-one patients with primary SS and 18 with secondary SS were followed for a mean of 39 +/- 20 months (range 11-112 months). During this observation period the lymphocytic infiltration in minor salivary glands, measured as focus score, increased in 14/21 (67%) patients with primary SS and in 14/18 (78%) patients with secondary SS. Altogether there was a statistically significant increase in focus score in both primary and secondary SS, but no reduction in salivary production. Consequently, no correlation between changes in focus score and stimulated salivary secretion was found in either primary or secondary SS.

Entities:  

Mesh:

Year:  1993        PMID: 8339128     DOI: 10.1093/rheumatology/32.7.578

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  24 in total

1.  Progression of salivary gland dysfunction in patients with Sjogren's syndrome.

Authors:  J Pijpe; W W I Kalk; H Bootsma; F K L Spijkervet; C G M Kallenberg; A Vissink
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

Review 2.  Animal models of Sjögren's syndrome.

Authors:  Malin V Jonsson; Nicolas Delaleu; Roland Jonsson
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.

Authors:  N Roescher; B M Lodde; J L Vosters; P P Tak; M A Catalan; G G Illei; J A Chiorini
Journal:  Oral Dis       Date:  2011-09-14       Impact factor: 3.511

4.  Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).

Authors:  M Pertovaara; M Korpela; H Uusitalo; J Pukander; A Miettinen; H Helin; A Pasternack
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

5.  Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.

Authors:  B M Lodde; F Mineshiba; J Wang; A P Cotrim; S Afione; P P Tak; B J Baum
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

6.  Salivary gland scintigraphy in Sjögren's syndrome and patients with sicca symptoms but without Sjögren's syndrome: the psychological profiles and predictors for salivary gland dysfunction.

Authors:  E-K Tensing; D C Nordström; S Solovieva; K-O Schauman; I Sippo-Tujunen; T Helve; S Natah; J Ma; T F Li; Y T Konttinen
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

7.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

Review 8.  Parasympathetic nervous system dysfunction in primary Sjögren's syndrome.

Authors:  A Hocevar; M Tomsic; S Praprotnik; M Hojnik; T Kveder; B Rozman
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

Review 9.  Diagnosis and treatment of xerostomia (dry mouth).

Authors:  Joel J Napeñas; Michael T Brennan; Philip C Fox
Journal:  Odontology       Date:  2009-07-29       Impact factor: 2.634

Review 10.  The genetics of primary Sjögren's syndrome.

Authors:  Amr H Sawalha; Robyn Potts; Wendi R Schmid; R Hal Scofield; John B Harley
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.